p.4 抽出テキスト

8.8. Metabolic syndrome, lipid abnormalities, diabetes mellitus, and hypertension ........................................................................................ 4318 8.9. Pregnancy in cancer survivors ..................................................... 4318 8.10. Pulmonary hypertension .............................................................. 4319 9. Special populations .................................................................................... 4319 9.1. Cardiac tumours ................................................................................ 4319 9.2. Pregnant patients with cancer ..................................................... 4319 9.2.1. Left ventricular dysfunction and heart failure ........ 4320 9.2.2. Venous thromboembolism and pulmonary embolism ..................................................................................... 4320 9.3. Carcinoid valvular heart disease ................................................. 4323 9.4. Amyloid light-chain cardiac amyloidosis .................................. 4324 9.5. Cardiac implantable electronic devices .................................... 4326 10. Patient information, communication, and self-management 4330 11. The role of scientific societies in the promotion and development of cardio-oncology in modern medicine .................. 4331 12. Key messages ............................................................................................ 4331 13. Future needs .............................................................................................. 4332 14. Gaps in evidence ...................................................................................... 4333 15. ‘What to do’ and ‘what not to do’ messages from the Guidelines ........................................................................................................... 4333 16. Quality indicators for cardio-oncology .......................................... 4342 17. Supplementary data ................................................................................ 4342 18. Data availability statement ................................................................... 4342 19. Author information ................................................................................ 4342 20. Appendix ..................................................................................................... 4342 21. References .................................................................................................. 4343

Tables of Recommendations

Recommendation Table 1 — Recommendations for a general approach to cardiovascular toxicity risk categorization ................. 4249 Recommendation Table 2 — Recommendations for electrocardiogram baseline assessment ................................................ 4251 Recommendation Table 3 — Recommendation for cardiac biomarker assessment prior to potentially cardiotoxic therapies . 4252 Recommendation Table 4 — Recommendations for cardiac imaging modalities in patients with cancer .......................................... 4253 Recommendation Table 5 — Recommendations for primary prevention of cancer therapy-related cardiovascular toxicity ......................................................................................................... 4256 Recommendation Table 6 — Recommendation for secondary prevention of cancer therapy-related cardiovascular toxicity ..... 4257 Recommendation Table 7 — Recommendations for baseline risk assessment and monitoring during anthracycline chemotherapy and in the first 12 months after therapy .............................................. 4259 Recommendation Table 8 — Recommendations for baseline risk assessment and monitoring during human epidermal receptor 2-targeted therapies and in the first 12 months after therapy ... 4260 Recommendation Table 9 — Recommendations for baseline risk assessment and monitoring during fluoropyrimidine therapy ..... 4261 Recommendation Table 10 — Recommendations for baseline risk assessment and monitoring during vascular endothelial growth factor inhibitors ............................................................................... 4264 Recommendation Table 11 — Recommendations for baseline risk assessment and monitoring during second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors ................................................................. 4267 Recommendation Table 12 — Recommendations for baseline risk assessment and monitoring during Bruton tyrosine kinase inhibitor therapy .............................................................................................. 4267 Recommendation Table 13 — Recommendations for baseline risk assessment and monitoring during multiple myeloma therapies ..................................................................................................... 4271 Recommendation Table 14 — Recommendations for baseline risk assessment and monitoring during combined rapidly accelerated fibrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor therapy ............................................... 4272 Recommendation Table 15 — Recommendations for baseline risk assessment and monitoring during immunotherapy ............... 4274 Recommendation Table 16 — Recommendations for baseline risk assessment and monitoring during androgen deprivation therapy for prostate cancer ....................................................................... 4276 Recommendation Table 17 — Recommendations for baseline risk assessment and monitoring during endocrine therapy for breast cancer .................................................................................................... 4276 Recommendation Table 18 — Recommendations for baseline risk assessment and monitoring during cyclin-dependent kinase 4/6 inhibitor therapy ...................................................................................... 4277 Recommendation Table 19 — Recommendations for baseline risk assessment and monitoring during anaplastic lymphoma kinase and epidermal growth factor receptor inhibitors ............... 4277 Recommendation Table 20 — Recommendations for baseline risk assessment and monitoring in patients receiving chimeric antigen receptor T cell and tumour-infiltrating lymphocytes therapies ............................................................................................................. 4279 Recommendation Table 21 — Recommendations for baseline risk assessment of patients before radiotherapy to a volume including the heart .......................................................................................... 4279 Recommendation Table 22 — Recommendations for baseline risk assessment in haematopoietic stem cell transplantation patients ................................................................................................................ 4281 Recommendation Table 23 — Recommendation for the management of cardiovascular disease and cancer therapy-related cardiovascular toxicity in patients receiving anticancer treatment ..................................................................................... 4282 Recommendation Table 24 — Recommendations for the management of cancer treatment-related cardiac dysfunction during anthracycline chemotherapy ........................................................ 4284 Recommendation Table 25 — Recommendations for the management of cancer treatment-related cardiac dysfunction during human epidermal receptor 2-targeted therapies ............... 4286 Recommendation Table 26 — Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis ............................................................... 4289 Recommendation Table 27 — Recommendations for the diagnosis and management of Takotsubo syndrome in patients with cancer ........................................................................................................ 4291 Recommendation Table 28 — Recommendations for the management of acute coronary syndromes in patients receiving anticancer treatment ..................................................................................... 4292 Recommendation Table 29 — Recommendation for the management of chronic coronary syndromes in patients receiving anticancer treatment ..................................................................................... 4293 Recommendation Table 30 — Recommendations for the management of valvular heart disease in patients receiving anticancer treatment ..................................................................................... 4293 Downloaded from academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 07 October 2026